Latest articles and price-sensitive announcements with AI sentiment classification.
The shares have fallen hard, but the business itself continues to grow at an impressive rate. The post Down 44%: Will you regret not buying Pro Medicus shares? appeared first on The Motley Fool Australia.
Highlights Pro Medicus bounced sharply late last week after a choppy stretch for richly priced software names Technology was the weakest sector on Tuesday as AI-linked stocks were offloaded across the board The imaging software group remains a reference point for quality growth on the local market Pro Medicus (ASX:PME), the Melbourne-based developer of the Visage cloud imaging platform used by radiology groups and hospital networks, has been in focus after a strong rebound last Friday placed ...
Pro Medicus Shares Reclaim Key Moving Averages: The Latest Look thebull.com.au
Can Pro Medicus (ASX:PME) keep the tech rebound alive this week? Kalkine Media
Highlights A radiology software leader is trying to prove artificial intelligence strengthens rather than erodes its platform Long contracts with big American health systems give the story a sturdier base than the share price suggests Healthcare has been one of the few areas to attract flows while the broader market slides Pro Medicus (ASX:PME), the Melbourne-based developer of the Visage medical imaging platform used by large hospital networks in the United States, is back in the spotlight a...
Pro Medicus (ASX:PME): Buy, Hold or Sell? What Analysts Think Following FY26 Kalkine
Life360 (ASX:360), (ASX:PME) & (ASX:WTC): Three ASX Growth Shares to Watch Kalkine Media
Learn Why The Bull Case For Pro Medicus Stock Could Change Following Board Appointment Simply Wall Street
Highlights Pro Medicus brings enterprise medical imaging software and a deeply embedded healthcare technology platform to the list. Harvey Norman combines retail operations with a significant property footprint across several international markets. Pinnacle Investment Management provides exposure to a multi-affiliate funds management platform with a distinctive operating model. Australias share market is entering a period where business quality, leadership continuity and the durability o...
Highlights A new independent board appointment took effect this month Healthcare led the local market on Monday Pro Medicus remains a premium-priced imaging software leader Pro Medicus (ASX:PME) is in focus on Tuesday after a new independent non-executive appointment to its board took effect at the start of October, adding deep technology and strategy experience to the medical imaging software group as healthcare led the local market in Monday's session. A new face on the board Pro Medicus co...
Pro Medicus And 2 Australian Founder Backed Stocks To Watch Simply Wall Street
Why Pro Medicus Ltd (ASX:PME) Has Caught Investors’ Attention Kalkine
Pro Medicus Limited (ASX:PME): FY2026 Results Highlight Cloud Imaging Growth and Expanding Contract Pipeline kalkine.com.au
Pro Medicus And 2 Australian Founder Run Stocks To Watch simplywall.st
Highlights A softer global equity tone is likely to increase attention on relative resilience across ASX sectors. Pro Medicus Ltd is assessed through the current growth shares backdrop rather than a directional share-price call. Operational adaptability and quality of growth and execution are the main themes to monitor. The ASX is confronting a more volatile cross-asset backdrop as higher yields and energy prices challenge sentiment. That makes Pro Medicus Ltd (ASX:PME) a timely case study in...
Highlights Pro Medicus is drawing attention this week as its market value sits at a steep multiple of annual revenue. The medical imaging software group recently reported record results, with margins widening further and contracted revenue climbing. A deep pipeline of US hospital contracts and new products in cardiology, pathology and AI underpin the growth story. Pro Medicus (ASX:PME) is back in focus this week as the market weighs its valuation against a record contract book, with the medic...
other announcement
Highlights Pro Medicus (ASX:PME) continues to expand its Visage medical imaging platform across international healthcare networks. Long-term hospital contracts support a compounding growth profile within Growth Stocks. New client wins remain the clearest signal of its ongoing trajectory. Healthcare technology with genuine international reach continues to be a compelling growth story on the ASX, and Pro Medicus (ASX:PME) remains one of the standout names within Growth Stocks. Through its Visag...
Highlights Pro Medicus (ASX:PME) continues to expand its Visage medical imaging platform across international healthcare networks. Long-term hospital contracts support a compounding growth profile within Growth Stocks. New client wins remain the clearest signal of its ongoing trajectory. Healthcare technology with genuine international reach continues to be a compelling growth story on the ASX, and Pro Medicus (ASX:PME) remains one of the standout names within Growth Stocks. Through its Visag...
Highlights Pro Medicus Limited is in focus after healthcare shares were among the notable gainers in todays ASX session. The same-day development puts attention on medical imaging software and market momentum within ASX Technical Analysis. Further relevance will depend on execution, follow-up disclosure and the next verifiable milestone. Pro Medicus Limited (ASX:PME) [ASX 200] is drawing attention in todays Australian market cycle after healthcare shares were among the notable gainers in toda...
Highlights Pro Medicus (ASX:PME) supplies cloud-based imaging software used by hospitals and radiology providers. Its Visage platform is designed to support AI-assisted diagnostic workflows across large medical datasets. Healthcare imaging remains one of the more established fields where automation has moved into practical use. Healthcare technology has quietly become one of the more compelling corners of the local market's automation story, and Pro Medicus (ASX:PME) sits at the centre of tha...
Highlights Pro Medicus enters the September market backdrop as clinical and regulatory developments sharpen attention around healthcare technology. Higher bond yields, oil volatility and uneven sector leadership are creating a more selective environment across Australian shares. Its medical imaging software model leaves the company particularly sensitive to execution, commercial adoption and changing valuation assumptions. The Australian share market is entering a more selective phase, w...
Highlights Pro Medicus reported another year of revenue and underlying profit growth. How recurring imaging-platform revenue and contract delivery drove FY. Read alongside Pro Medicuss existing operating narrative, the disclosure refines rather than replaces what the market already knew. According to the latest release from Pro Medicus (ASX:PME), a member of the [ASX 200], pro Medicus reported another year of revenue and underlying profit growth. Nothing beyond that statement has been confirm...
PME, IDX and DOC: Three ASX Digital Healthcare Stocks on the Radar This September Kalkine
Highlights The medical imaging software group has strung together a run of American contract renewals across large health networks. [ASX 100] Its forward contracted revenue now stretches across a multi-year horizon, giving unusual visibility for a software business. A cardiology imaging module has been attached to a major renewal, widening the product beyond radiology alone. Pro Medicus (ASX:PME) has spent the year renewing rather than merely winning, signing extended agreements with United S...
Highlights Long bond yields at multi-year highs weigh hardest on the most richly rated growth names. The contract cadence across American hospital networks has kept running through the year. Healthcare led the local market lower, adding sector pressure on top of the macro move. Pro Medicus (ASX:PME) heads into the end of the week facing the same problem confronting every richly rated growth name on the local market. Long bond yields have surged to their highest levels in years, and that is pr...
Highlights Pro Medicus has a fresh disclosure linked to software deployment, recurring fees and clinical workflow value. The Visage imaging platform and contracted health networks remain central to the operating assessment. Execution, cash discipline and disclosure continuity remain the clearest markers. [ASX 50] Pro Medicus (ASX:PME) is back in focus after fresh annual reporting highlighted continued revenue growth from imaging software. The timely update directs attention to the Visage imag...
Highlights [ASX 50] Pro Medicus has placed its recent result and distribution disclosure amid continued imaging-platform expansion into the current public record. The market debate now turns toward execution quality, cash conversion, and financial flexibility. Later disclosures will show whether the latest development changes durable business economics. Pro Medicus (ASX:PME) has returned to market attention after its recent result and distribution disclosure amid continued imaging-platform ex...
Pro Medicus (ASX:PME) in Focus as FY27 Execution Becomes the Next Test Kalkine
Pro Medicus And 2 Australian Quality Stocks To Watch simplywall.st
Pro Medicus (ASX:PME) Draws Attention as Premium Medical Imaging Stock Approaches Monday Ex-Dividend Date Kalkine
A decade turned $10,000 into roughly $346,000. The post How much would $10,000 invested 10 years ago in Pro Medicus shares be worth today? appeared first on The Motley Fool Australia.
Highlights A large slate of new North American hospital agreements was signed across the financial year Operating margins expanded again and the balance sheet carries no debt The fully franked dividend was lifted materially alongside the full-year accounts Pro Medicus Limited (ASX:PME) closed its financial year with the largest slate of new contract wins it has ever recorded, and the medical imaging software group is now being judged on whether that order book converts into revenue as smoothl...
Highlights The medical imaging software group posted record revenue growth and a further expansion in operating margin for the year just ended. New contract wins across the period reached a record aggregate value, predominantly across United States health networks. Forward contracted recurring revenue expanded sharply, extending visibility well beyond the current financial year. Pro Medicus (ASX:PME), the Melbourne-based developer of diagnostic imaging software used across large hospital and ...
Highlights The medical imaging software group lifted operating margins to a level rarely seen in listed technology anywhere. Constant currency earnings growth ran well ahead of what the market had built into its expectations. Contract wins across large American health networks continue to underwrite the revenue pipeline. Pro Medicus (ASX:PME) is drawing a sharper market lens as sector conditions and company execution intersect across Australian equities. Pro Medicus (ASX:PME), the medical ima...
Highlights The medical imaging software group has delivered what it describes as its strongest annual performance to date, with revenue and underlying earnings both advancing. Shares moved firmly higher once the release hit the screens, clawing back part of a bruising run through the past financial year. Momentum with North American health networks remains the engine of the story, and the market is watching renewal timing closely. Australian market attention has shifted toward Pro Medicus (AS...
Highlights The medical imaging software group was among the standout gainers on the local board last week. Contract wins across North American health networks have lifted the contracted revenue base. A premium multiple leaves little tolerance for any stumble in execution. Pro Medicus (ASX:PME) is drawing a sharper market lens as sector conditions and company execution intersect across Australian equities. Pro Medicus (ASX:PME) featured among the standout gainers on the local board late last w...
Highlights Pro Medicus is drawing attention as scalable healthcare software expansion becomes more important to the Australian market conversation. The companys position across the Visage imaging platform and a growing base of large healthcare customers gives readers a practical lens on changing conditions in medical imaging technology. Operational delivery, capital discipline and clear strategic priorities remain central as the sector continues evolving. Australias sharemarket is entering a ...
Highlights Pro Medicus delivered a record annual outcome, with margin expansion across its medical imaging software platform drawing an enthusiastic market reaction. A fresh stake in an imaging technology developer adds an early-stage growth avenue alongside the core radiology software offering. New artificial intelligence reporting tools introduced during the period could widen the platform's value proposition for radiology customers over coming periods. Pro Medicus Limited (ASX:PME) [ASX 10...
Pro Medicus (ASX:PME) FY26 Results Showcase Exceptional Growth and High-Margin Healthcare Software Model Kalkine
Highlights Pro Medicus delivered a stronger FY26 operating result as expanding Visage adoption and new contract activity reinforced the scalability of its medical-imaging software platform. The latest dividend increase adds another dimension to the story, but recurring software demand, contract conversion and deployment execution remain the more durable operating signals. Future disclosures should show whether North American momentum, cloud adoption and implementation capacity can continue supp...
Pro Medicus Ltd (ASX:PME) Shares Are Moving: What's Driving Investor Interest? Kalkine
Pro Medicus (ASX:PME) Tests Its Valuation Narrative On Annual Results And Dividend simplywall.st
Highlights Pro Medicus is being assessed through demand durability, product adoption and the quality of execution rather than short-term market direction. The healthcare stocks backdrop makes margin quality and research investment especially useful when separating company evidence from sector noise. Upcoming disclosures can clarify whether global execution is supporting or constraining the operating story around Pro Medicus. A choppy Australian market has made business quality easier to disti...
The tech stock has announced another contract win this morning. The post Pro Medicus signs A$25m US contract: What it means for investors appeared first on The Motley Fool Australia.
other announcement
Highlights Rather than begin with the market narrative, this section starts inside Pro Medicus: procedure volumes is tested against regulatory pathway before the [ASX 100] context is considered. This coverage treats Pro Medicus as an operating case study, beginning with regulatory pathway and then testing procedure volumes. Pro Medicus is better understood through the economics of medical imaging software than through a broad growth-stock template. The healthcare version of the story centres on...
Highlights This is where Pro Medicus departs from a category-wide template. The key is whether execution pace and reinvestment quality move in a way that supports the economics implied by margin progression. Pro Medicus is read through execution pace first, with margin progression acting as the next confirmation point. The coverage separates company execution from the wider ASX 200 backdrop instead of treating the market move as the conclusion. Reinvestment quality provides the counter-check th...
Highlights Pro Medicus (ASX:PME) continues to expand its dividend alongside growth in its medical imaging software business. The companys Visage imaging technology supports healthcare organisations through cloud-based diagnostic imaging workflows. Regular dividend increases highlight the companys expanding capacity to return capital to shareholders. Full franking adds another feature to its dividend profile for eligible Australian shareholders. Business growth, customer expansion and the sustain...
Pro Medicus (ASX:PME) Shares Command Perfection As Non Cash Profit Concerns Linger simplywall.st
Highlights The 19 August reporting calendar includes ARB Corporation, Bega Cheese, Breville Group, BWP Trust and Deterra Royalties among companies scheduled to report. Pro Medicus (ASX:PME) is the primary company lens, while BHP Group (ASX:BHP), CSL (ASX:CSL), Commonwealth Bank of Australia (ASX:CBA) provide category context. The article focuses on price leadership, sector breadth and earnings-driven momentum without using directional investment recommendations. The tape is unusually event-dr...
Highlights BHP reported FY26 results on 18 August, with copper overtaking iron ore as its largest earnings contributor and the company highlighting strong cash generation. Pro Medicus (ASX:PME) is the primary company lens, while ResMed (ASX:RMD), CSL (ASX:CSL), Cochlear (ASX:COH) provide category context. The article focuses on earnings quality, product demand and healthcare growth durability without using directional investment recommendations. The central question for healthcare stocks is n...
Highlights On 18 August, the [S&P/ASX 200] finished at, down points, while the [All Ordinaries] closed at. Pro Medicus (ASX:PME) is the primary company lens, while WiseTech Global (ASX:WTC), REA Group (ASX:REA), TechnologyOne (ASX:TNE) provide category context. The article focuses on scalable revenue, margin expansion and reinvestment capacity without using directional investment recommendations. The central question for growth stocks is no longer simply whether the macro backdrop is supp...
Pro Medicus shares rocket on FY26 results and FY27 could be even better Market Index
Why Pro Medicus Stock (ASX:PME) Is Up 12% Today, FY26 Profit Surges 130% kalkine.com.au
Highlights Imaging software scale through hospital deployments is the central company-specific issue, with contract wins providing the first operating check. Deployment pace and recurring licences show whether activity is translating into commercial quality and financial discipline. High expectations and lengthy customer implementation remains the main constraint that could interrupt the operating sequence. The latest company updates are putting a sharper premium on evidence that can be trace...
Highlights Contract growth with deployment discipline is the central company-specific issue, with new contracts providing the first operating check. Deployment timing and recurring licence revenue show whether activity is translating into commercial quality and financial discipline. High market expectations and lengthy hospital implementation remains the main constraint that could interrupt the operating sequence. Reporting season often rewards the clearest operating explanation rather than t...
Highlights Shares were among the session's notable decliners as the medical imaging software group heads into its full-year results, extending a technical pullback that has weighed on the stock over recent months. No fresh earnings update, contract announcement or guidance revision has emerged to explain the recent weakness, pointing to valuation sensitivity and technical repositioning rather than any change in the underlying business. The flagship Visage imaging platform continues to expand it...
Motley Fool
Kalkine
Google News
ASX